Clinical Trials and Research

HighlightsThis is the first published study specifically targeting cardiac amyloidosis screening in patients presenting with coronary artery disease.Screening for…

Department of Vascular Surgery, Beijing Haidian Hospital, Beijing, People’s Republic of China; 2Department of Hematology, Beijing Chao-Yang Hospital, Capital…

Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with the rare heart…

AbstractAccurate amyloid typing in cardiac amyloidosis is clinically important for determining treatment strategies. A 73-year-old man underwent a renal biopsy due…

HighlightsSubtle age-related ATTR-CM can complicate preexisting other HF etiologies.Combined cardiomyopathies can present with atypical clinical/imaging…

SummaryOnce rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific…

AbstractIntroduction: Cardiac amyloidosis (CA), including transthyretin (ATTR) and light-chain (AL) subtypes, is an underrecognized mimic of heart failure with…

Long-term treatment with Amvuttra (vutrisiran) was found to be safe and to sustain disease stability in people with hereditary transthyretin amyloidosis with…

Long-term treatment with Amvuttra (vutrisiran) was found to be safe and to sustain disease stability in people with hereditary transthyretin amyloidosis with…

AbstractBACKGROUND:Acoramidis achieves near-complete (≥90%) transthyretin stabilization and is approved to reduce cardiovascular-related hospitalization in…